Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 Days (EBA Study)

Colony-forming units of Mycobacterium tuberculosis in sputum were drug activity that is deemed necessary by the Food and Drug counted at 2-day intervals in 100 patients treated with 22 regimens. Administration for licensing new antituberculosis drugs. of isoniazid, rifampin, pyrazinamide, ethambutol, or streptomycin, A major drawback of the EBA technique is that it does given alone or in combinations. The exponential fall in colony- not measure the sterilizing activity of a drug against bacilli that forming units was measured by linear regression coefficients of the persist despite effective drug treatment and are responsible for log counts during the initial 2-day phase of rapid, drug-determined prolonging the treatment period. The possibility of detecting killing and during the subsequent 12 days of much slower sterilizing the sterilizing activity of rifampin by prolonging the study activity. The regression coefficients during the first 2 days varied period beyond Day 2 (termed extended EBA) has been raised significantly according to the drug; the greatest effects in multiple (7, 8). These suggestive results need confirmation.

在痰液中分离出的结核分枝杆菌形成单位，其药物活性评估由食品药品监督管理局认定为必要的，在100名接受22种治疗方案治疗的病人中，以2天为间隔进行计数。此评估用于新抗结核药物的许可审批。异烟肼、利福平、吡嗪酰胺、乙胺丁醇或链霉素的单独使用或联合应用均存在显著缺陷，即该技术无法测量药物对持续存在有效药物治疗的细菌的灭菌活性，而这些细菌是导致治疗周期延长的主要原因。通过延长研究周期，即所谓的扩展EBA（Extended Bacterial Agar），检测利福平的灭菌活性成为可能，这种灭菌活性的检测在研究的最初2天快速杀菌阶段通过线性回归系数的log计数进行，而在随后的12天较慢的灭菌活性阶段进行。前2天的回归系数根据药物的不同而有显著变化（例如7、8倍），这些具有提示性的结果需要进一步的确认。